18F-FDG PET-CT在软组织肉瘤中的应用：分期、再分期及预后价值？

18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?

作者信息

Gabriel Michael, Rubello Domenico

机构信息

aDepartment of Nuclear Medicine and Endocrinology, Allgemeines Krankenhaus der Stadt Linz, Medical Faculty of the Johannes Kepler University, Linz bUniversity Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria cNuclear Medicine & PET/CT Centre Department, Santa Maria della Misericordia Hospital, Rovigo, Italy.

出版信息

Nucl Med Commun. 2016 Jan;37(1):3-8. doi: 10.1097/MNM.0000000000000407.

DOI:10.1097/MNM.0000000000000407

PMID:26457597

Abstract

The aim of this article was to review the current role of PET/computed tomography (CT) in soft tissue sarcomas with respect to staging, restaging, and prognostic value. Fluorine-18-fluorodeoxyglucose PET, for instance, can be very useful in differentiating recurrent disease from scar tissue during follow-up. Other indications of PET-CT are still evolving, especially in the light of new molecular drugs. Different aspects of PET/CT imaging in soft tissue sarcomas are overviewed including organ-specific merits, limitations, and potential pitfalls. Finally, methodological considerations on PET/MRI are also briefly discussed.

摘要

本文旨在综述正电子发射断层扫描/计算机断层扫描（PET/CT）在软组织肉瘤的分期、再分期及预后价值方面的当前作用。例如，氟-18-氟脱氧葡萄糖PET在随访期间区分复发疾病与瘢痕组织方面可能非常有用。PET-CT的其他应用仍在不断发展，尤其是鉴于新型分子药物的出现。本文概述了PET/CT在软组织肉瘤成像中的不同方面，包括器官特异性优点、局限性及潜在陷阱。最后，还简要讨论了PET/MRI的方法学考量。